Study of SHEN26 Capsule in Patients With Mild to Moderate COVID-19
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II
clinical trial. It is designed to evaluate the efficacy, safety, tolerability, and
pharmacokinetic (PK) profile of SHEN26 capsules in Chinese patients with mild to moderate
COVID-19.